Otzela

The Biopharma Patent Cliff: 9 Drugs Losing Exclusivity by the End of 2023
BioSpace
Wed, 08/23/23 - 11:11 am
patent cliff
patents
Takeda
Vyvanse
Pfizer
Eraxis
JNJ
Stelara
Merck
Isentress
Eiger Pharmaceuticals
Zokinvy
Astellas
Myrbetriq
Novartis
Entresto
Amgen
Otzela
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Fierce Biotech
Thu, 10/7/21 - 11:24 am
Bristol Myers Squibb
deucravacitinib
Amgen
Otzela
psoriasis
ulcerative colitis
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivals
Fierce Pharma
Wed, 07/29/20 - 12:31 pm
Otzela
Celgene
Amgen
psoriasis
COVID-19
Celgene's $13.4 Billion Deal With Amgen Is a Win-Win-Win
Motley Fool
Mon, 08/26/19 - 10:56 pm
Amgen
Celgene
Otzela
FDA Approves First Treatment for Oral Ulcers Associated with Rare Inflammatory Disease
BioSpace
Mon, 07/22/19 - 11:41 am
Otzela
Celgene
FDA
Behcet's disease